Yuan Zhi
Stock Analyst at B. Riley Securities
(4.59)
# 933
Out of 4,491 analysts
127
Total ratings
43.4%
Success rate
24.3%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WHWK Whitehawk Therapeutics | Initiated Coverage: Buy | $10 | $4.15 | +140.96% | 1 | Jun 25, 2026 | |
| TNGX Tango Therapeutics | Rated: Buy | $21 → $35 | $30.12 | +16.20% | 7 | Jun 9, 2026 | |
| HYPR Hyperfine | Rated: Buy | $1.6 → $2 | $1.22 | +63.93% | 8 | May 13, 2026 | |
| RDNT RadNet | Rated: Buy | $87 → $83 | $67.83 | +22.36% | 6 | May 1, 2026 | |
| LNTH Lantheus Holdings | Rated: Buy | $84 → $97 | $103.41 | -6.20% | 25 | May 1, 2026 | |
| SRTA Strata Critical Medical | Initiated Coverage: Buy | $8 | $5.24 | +52.67% | 1 | Mar 25, 2026 | |
| CATX Perspective Therapeutics | Rated: Buy | $11 → $13 | $3.42 | +280.12% | 13 | Mar 18, 2026 | |
| FHTX Foghorn Therapeutics | Maintained: Buy | $10 | $6.00 | +66.67% | 2 | Dec 17, 2025 | |
| RADX Radiopharm Theranostics | Maintained: Buy | $13 → $16 | $4.24 | +277.36% | 6 | Dec 16, 2025 | |
| MIR Mirion Technologies | Maintained: Buy | $22 → $29 | $16.06 | +80.57% | 9 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $5.80 | +3.45% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 → $3 | $0.4068 | n/a | 3 | Oct 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $16 → $2 | $1.05 | n/a | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $19 → $15 | $15.07 | n/a | 14 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $79 | $25.37 | n/a | 12 | Feb 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $34 | $27.93 | n/a | 5 | Jan 9, 2023 |
Whitehawk Therapeutics
Jun 25, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $4.15
Upside: +140.96%
Tango Therapeutics
Jun 9, 2026
Rated: Buy
Price Target: $21 → $35
Current: $30.12
Upside: +16.20%
Hyperfine
May 13, 2026
Rated: Buy
Price Target: $1.6 → $2
Current: $1.22
Upside: +63.93%
RadNet
May 1, 2026
Rated: Buy
Price Target: $87 → $83
Current: $67.83
Upside: +22.36%
Lantheus Holdings
May 1, 2026
Rated: Buy
Price Target: $84 → $97
Current: $103.41
Upside: -6.20%
Strata Critical Medical
Mar 25, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $5.24
Upside: +52.67%
Perspective Therapeutics
Mar 18, 2026
Rated: Buy
Price Target: $11 → $13
Current: $3.42
Upside: +280.12%
Foghorn Therapeutics
Dec 17, 2025
Maintained: Buy
Price Target: $10
Current: $6.00
Upside: +66.67%
Radiopharm Theranostics
Dec 16, 2025
Maintained: Buy
Price Target: $13 → $16
Current: $4.24
Upside: +277.36%
Mirion Technologies
Oct 28, 2025
Maintained: Buy
Price Target: $22 → $29
Current: $16.06
Upside: +80.57%
Sep 5, 2025
Maintained: Buy
Price Target: $6
Current: $5.80
Upside: +3.45%
Oct 2, 2024
Reiterated: Buy
Price Target: $4 → $3
Current: $0.4068
Upside: n/a
Aug 7, 2024
Downgraded: Hold
Price Target: $16 → $2
Current: $1.05
Upside: n/a
Jul 30, 2024
Upgraded: Buy
Price Target: $19 → $15
Current: $15.07
Upside: n/a
Feb 7, 2024
Reiterated: Buy
Price Target: $79
Current: $25.37
Upside: n/a
Jan 9, 2023
Maintained: Buy
Price Target: $34
Current: $27.93
Upside: n/a